Immunotherapy shows promise, but reliable biomarkers for effectiveness are still missing, particularly regarding the influence of HPV status and tumor location in head and neck cancers.*
-
A study analyzed tumor samples from 106 patients, revealing that PD-L1 positivity in immune cells is linked to better survival rates, especially in HPV-negative laryngeal cancers.*
-
While PD-L1 and PD-1 status correlated well in most patients, no significant immunological differences were noted among various tumor locations, although hypopharyngeal cancers may require additional study.*